Skip to main content
Premium Trial:

Request an Annual Quote

Icoria to Identify Hepatocyte Biomarkers for ADMET Techologies

NEW YORK, April 19 (GenomeWeb News) - Icoria said today that it will use its metabolomics and gene-expression technology to characterize ADMET Technologies' human adult hepatocytes for predictive toxicology screening.


Under the agreement, ADMET will provide Icoria with liver cells from patients with a diversity of medical conditions. Icoria will then use its metabolomics, gene expression, and pathway analysis technologies to develop biological profiles and correlate these with differing sensitivities to various classes of hepatotoxic drugs, the companies said.


Icoria will retain the rights to commercial development of any novel diagnostic biomarkers discovered during the research. Further financial details were not disclosed.


In March, Icoria announced it was selling its agricultural genomics assets to Monsanto, and would reposition itself to focus on biomarker discovery for diabetes, obesity, and liver injury using its metabolomics, gene-expression profiling, tissue analysis software, and computational assets.

The Scan

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.